Research and Markets: Neurodegenerative Diseases Market to 2018: New Entries in Niche and Broader Parkinson's Disease …

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/9nt469/neurodegenerative) has announced the addition of the "Neurodegenerative Diseases Market to 2018 - New Product Entries in both Niche and Broader Parkinson's Disease Treatment will Boost Market Despite Patent Cliff" report to their offering.

Global Neurodegenerative Diseases Market to Witness Moderate Growth

The global neurodegenerative diseases market is expected to grow moderately from $8.8 billion in 2012 to $11 billion in 2018 at a Compound Annual Growth Rate (CAGR) of 1.8% from 2012-2015 and at a higher CAGR of 5.9% from 2015-2018. A number of competitive market entries are expected across all four indications during the forecast period, mitigating the effects of numerous patent expiries. In addition, growth in the population over the age of 65 across the seven major markets is expected to further drive this growth. The impact of these market entries is expected to present itself after 2015.

Alzheimer's Disease and Parkinson's Disease Therapeutics Account for the Majority of the Global Neurodegenerative Diseases Market

Due to their comparatively low prevalence rates, Huntington's Disease (HS) and Amyotrophic Lateral Sclerosis (ALS) have relatively small disease markets. Parkinson's Disease (PD) and Alzheimer's Disease (AD) are the two dominant indications in the overall neurodegenerative diseases market. Due to the anticipated approval of a number of competitive treatments during the forecast period, the PD market is expected to contribute far more to the overall neurodegenerative diseases market by 2018.

Strong Product Pipeline to Ensure the Future Growth of the Neurodegenerative Diseases Market

In spite of a number of high-profile clinical trial failures such as bapineuzumab and, to an extent, solanezumab for the treatment of AD, the overall pipeline for neurodegenerative diseases remains strong. It contains an estimated 678 pipeline products, most of which are being developed for the treatment of AD or PD. There are relatively few products in Phase III development, although Phases I and II are relatively populated with a variety of molecules. The largest stage of development in terms of the number of molecules is the Preclinical stage, which accounts for 42% of the pipeline with 288 molecules identified at this stage.

Key Topics Covered:

1 Tables & Figures

2 Introduction

Here is the original post:
Research and Markets: Neurodegenerative Diseases Market to 2018: New Entries in Niche and Broader Parkinson's Disease ...